Anakinra

ApprovedRecruiting

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Familial Mediterranean Fever (FMF )

Conditions

Familial Mediterranean Fever (FMF )

Trial Timeline

Sep 1, 2025 → Nov 30, 2027

NCT ID

NCT06666335

About Anakinra

Anakinra is a approved stage product being developed by Swedish Orphan Biovitrum for Familial Mediterranean Fever (FMF ). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06666335. Target conditions include Familial Mediterranean Fever (FMF ).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06666335	Approved	Recruiting	Sep 1, 2025	Nov 30, 2027	Familial Mediterranean Fever (FMF )
NCT04359784	Phase 2	Completed	Dec 27, 2021	Dec 23, 2024	B-Cell Non-Hodgkin Lymphoma
NCT04018755	Phase 1/2	Completed	Jan 30, 2020	Mar 8, 2023	Mucopolysaccharidosis III
NCT03932344	Pre-clinical	Completed	Apr 10, 2019	Aug 31, 2019	Still Disease, Juvenile Onset
NCT02390596	Phase 2	Completed	Feb 5, 2016	Feb 18, 2019	Kawasaki Disease
NCT02915094	Pre-clinical	Completed	Oct 1, 2012	Jan 1, 2016	Rheumatoid Arthritis

Competing Products

20 competing products in Familial Mediterranean Fever (FMF )

See all competitors

Product	Company	Stage	Hype Score
Bromocriptine Mesilate + Placebos	Towa Pharmaceutical	Phase 1/2	40
SHR-1209	Jiangsu Hengrui Medicine	Phase 2	52
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo	Jiangsu Hengrui Medicine	Phase 3	77
Rosuvastatin 20mg + Placebo	AstraZeneca	Phase 3	77
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium	AstraZeneca	Phase 3	77
Rosuvastatin + Placebo	AstraZeneca	Phase 3	77
Rosuvastatin 20mg	AstraZeneca	Phase 3	77
AZD0780 + Placebo	AstraZeneca	Phase 3	77
Anacetrapib + Placebo for anacetrapib	Merck	Phase 3	77
Statins and Ezetimibe	Merck	Pre-clinical	23
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo	Merck	Phase 3	77
MK-0524A + MK-0524A	Merck	Phase 1	33
Enlicitide Decanoate + Placebo	Merck	Phase 2/3	65
Inclisiran + Placebo	Novartis	Phase 3	77
DFV890	Novartis	Phase 2	52
Canakinumab	Novartis	Phase 2	52
Inclisiran Sodium for injection + Placebo + Placebos	Novartis	Phase 3	77
LCQ908 + Placebo	Novartis	Phase 3	77
Inclisiran	Novartis	Phase 3	77
Inclisiran + Placebo	Novartis	Phase 3	77

Other Products from Swedish Orphan Biovitrum

Recombinant coagulation factor (rFVIIIFc)Approved

rFVIIIFcApproved

Efanesoctocog alfaApproved

Kepivance (Palifermin)Approved

Emapalumab-Lzsg 5 MG/ML [Gamifant]Approved